Edwards Lifesciences
1,262 hedge funds and large institutions have $39.3B invested in Edwards Lifesciences in 2025 Q2 according to their latest regulatory filings, with 164 funds opening new positions, 422 increasing their positions, 460 reducing their positions, and 92 closing their positions.
78% more first-time investments, than exits
New positions opened: 164 | Existing positions closed: 92
70% more call options, than puts
Call options by funds: $254M | Put options by funds: $149M
5% more funds holding
Funds holding: 1,207 → 1,262 (+55)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
0.6% less ownership
Funds ownership: 86.28% → 85.68% (-0.6%)
5% less capital inflows, than outflows
Capital inflows: $3.35B | Capital outflows: $3.52B
8% less repeat investments, than reductions
Existing positions increased: 422 | Existing positions reduced: 460
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$359M |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$358M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$288M |
| 4 |
Millennium Management
New York
|
+$241M |
| 5 |
Jennison Associates
New York
|
+$118M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
-$730M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$694M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$396M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$120M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$78.3M |
EW Hedge Fund Activity: Q2 2025 in Review
1,262 of the 7,623 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q2 2025, worth a combined $39.3B — up 7.2% from $36.6B a quarter earlier.
Buyers outnumbered sellers: 164 funds opened new EW positions and 92 closed out — a net gain of 72 holders — while 422 added to existing stakes and 460 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $359M. The largest seller was Fisher Asset Management, cutting an estimated $730M.
- 1,262 institutional investors held Edwards Lifesciences (EW) as of Q2 2025, up from 1,207 in Q1 2025.
- Funds reported $39.3B of Edwards Lifesciences stock for Q2 2025, up 7.2% quarter-over-quarter.
- 164 funds opened new Edwards Lifesciences positions in Q2 2025 and 92 closed out, a net change of +72 holders.
- The largest Edwards Lifesciences buyer in Q2 2025 was JP Morgan Chase, an estimated $359M added.
- The largest Edwards Lifesciences seller in Q2 2025 was Fisher Asset Management, an estimated $730M sold.
Based on aggregated 13F filings for Q2 2025.